Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113530 | 0.89 | MYC (0.32) | MYCCYP2C9CYP2C19 | |
| SCHEMBL4099220 | 0.89 | CRHR1 (0.34) | KDR | |
| SCHEMBL4111997 | 0.86 | CYP2C9 (0.37) | MYCCYP2C9CYP2C19ITKKDR | |
| SCHEMBL13517073 | 0.86 | CRHR1 (0.31) | MYC | |
| SCHEMBL4110951 | 0.78 | CRHR1 (0.34) | — | |
| SCHEMBL4106712 | 0.77 | CYP2C19 (0.50) | CYP2C9CYP2C19MAPKAPK2 | |
| SCHEMBL10195623 | 0.77 | MYC (0.32) | MYCCYP2C9CYP2C19SCN9A | |
| SCHEMBL4110252 | 0.76 | CYP2C9 (0.35) | MYCCYP2C9CYP2C19SCN9A | |
| SCHEMBL3842214 | 0.73 | CRHR1 (0.36) | CYP2C9CYP2C19KDRSCN9A | |
| SCHEMBL10476742 | 0.72 | LATS1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | MYC 2371/4885CYP2C9 2156/4885CYP2C19 1979/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | MYC 2371/4885CYP2C9 2156/4885CYP2C19 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.